Motilal Oswal Alternates Acquires Majority Stake In Mega Fine Pharma For Rs 460 Crore
Mega Fine Pharma has USFDA-approved manufacturing facilities in Nashik and Vapi and makes high-value, low-volume niche APIs for chronic therapies.
Motilal Oswal Alternates on Tuesday announced a Rs 460-crore investment in Mega Fine Pharma Pvt. for a majority stake.
The Sanghvi family, the promoters of the company, have also invested in a bid to increase their stake in the export-focused integrated API company, according to an official statement.
The Mumbai-headquartered company was established in 1995, and has two USFDA-approved manufacturing facilities in Nashik and Vapi. It makes high-value, low-volume niche active pharmaceutical ingredients for chronic therapies.
Motilal Oswal Alternates' practical approach and deep expertise in life sciences will be instrumental in transforming the company into a long-lasting institution, the company's promoter Shailesh Sanghvi, who is now appointed as the managing director, said.
Rohit Mantri, co-head of private equity at MO Alts said the API industry is witnessing double-digit growth in India driven by higher outsourcing, lower costs and de-risking of global supply chains from China and added that this is the first sole control investment for the fund.
The PE fund will focus on strengthening research and development and manufacturing capabilities and creating a platform for further inorganic opportunities, he added.
